Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129059) titled 'Efficacy and safety of ruxolitinib phosphate cream in treating non-segmental vitiligo in adolescents (12 to 18 years old)' on July 29.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Children's Hospital of Fudan University
Condition:
Vitiligo
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-08-04
Target Sample Size: Treatment group:100;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=334551
Published by HT Digital Content Services with permission from Health Daily Digest....